Business Wire

QUOTIENT-SCIENCES

25.8.2021 14:02:08 CEST | Business Wire | Press release

Share
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility

Quotient Sciences , the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.

Quotient acquired the Alnwick facility from Arcinova in February 2021 to expand its service portfolio to include drug substance, drug product and clinical testing capabilities all under one organization. The acquisition enables Quotient to support customers with an “end to end” offering from candidate selection through commercial product launch. The multimillion-pound investment will repurpose a 1,500 square-meter footprint and incorporate additional equipment and technologies — significantly expanding the number of new molecules developed each year.

Additional equipment, featuring the latest advances in digital control and data capture, will ensure robust transfer from laboratory to multi-kilo scale production. Plus, processing equipment with new developments in modular continuous technology will maximize responsiveness and agility for manufacturing processes. These updates, combined with a five-fold increase in scale, will increase Quotient’s capacity by over 10 times for developing complex medicines.

“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Quotient Sciences SVP Candidate Development Services Roger Kilburn . “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”

The Alnwick facility employs 170 people across a range of scientific disciplines, and this investment will create a variety of new jobs. Quotient continues to grow and was recently presented an award for “Most Inspirational North East (U.K.) Science Employer,” from STEM Learning, as part of the STEM Ambassadors program.

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 15:00:00 CEST | Press release

Fund VIII Reflects Strong Global Investor Support for Clearlake’s Integrated Platform, Operational Value-Creation Model, and AI-Enabled Investment Approach Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's different

Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 15:00:00 CEST | Press release

Awards recognize foundational research that helped shape the fields of mixed-integer and nonlinear optimization—and reflect the company’s deep scientific roots. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.”

Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 15:00:00 CEST | Press release

Leveraging Airship’s Customer Experience Platform, Germany’s leading digital news publisher transforms reader engagement and captures 822 active responses in a single day. Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarel

New CSC Report Illustrates How AI Is Affecting Enterprise Security Leaders16.6.2026 15:00:00 CEST | Press release

CISO Outlook 2026 report indicates 73% of security leaders view AI as an opportunity rather than a risk, however traditional and AI-driven cyber threats persist CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today released new research on how chief information security officers (CISOs) are adapting to an evolving artificial intelligence (AI) ecosystem while managing traditional cyber threats, such as DNS outages. According to CSC’s CISO Outlook 2026 report, 73% of respondents say AI presents more of an opportunity than a risk for cybersecurity. However, these security leaders continue to face challenges in addressing attacks, including AI-powered domain generation algorithms (DGAs), which 86% of respondents cite as a threat. To thoroughly understand the CISO perspective on today’s cybersecurity landscape, CSC surveyed 300 senior executives—including CISOs, chief technology officers (CTOs), chief infor

TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 14:30:00 CEST | Press release

New capability allows developers and AI agents to validate network activity, console logs, browser storage, and performance metrics without writing custom scripts TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye